Hosted on MSN15d
Eli Lilly pays $10m upfront for Organovo’s FXR agonistOrganovo expressed enthusiasm about continuing FXR314’s development in MASH. However, in its announcement with Lilly, the company only mentions its focus on IBD. A Phase II trial in IBD is planned, ...
Hosted on MSN1mon
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASHEli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...
OliX selected the target after looking at genomic variants linked to MASH and other liver diseases. The Korean biotech is running a phase 1 trial of the candidate in healthy volunteers, and Lilly ...
A case study on how DelveInsight helped a pharma client navigate the evolving metabolic dysfunction-associated steatohepatitis (MASH) landsca ...
On Monday, Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated steatohepatitis (MASH), respectively. AdvanCell announced that it ...
Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...
a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications. OliX will receive an initial payment from Lilly to complete the Phase 1 ...
Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH FXRs, short for farnesoid X receptors, are nuclear receptors mainly expressed in the liver and ...
The acquisition highlights FXR314’s commercial potential in MASH patients with combination therapy. Lilly could use FXR314 possibly with its anti-diabetic and obesity drug, tirzepatide.
Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a phase 1 candidate for metabolic-associated steatohepatitis (MASH) and other ...
Eli Lilly (NYSE: LLY) stock defied today's market ... colitis and metabolic dysfunction-associated steatohepatitis (MASH). Where to invest $1,000 right now? Our analyst team just revealed what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback